我们如何监测乳腺癌幸存者的心脏健康。
How We Monitor Cardiac Health in Breast Cancer Survivors.
作者信息
Clasen Suparna C, Miller Meagan E
机构信息
Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.
出版信息
J Clin Oncol. 2025 Jan;43(1):4-9. doi: 10.1200/JCO.24.00757. Epub 2024 Sep 3.
Abstract
Journal Journal of Clinical Oncology
摘要
《临床肿瘤学杂志》
相似文献
1
How We Monitor Cardiac Health in Breast Cancer Survivors.我们如何监测乳腺癌幸存者的心脏健康。
J Clin Oncol. 2025 Jan;43(1):4-9. doi: 10.1200/JCO.24.00757. Epub 2024 Sep 3.
2
Late Breast Cancer Survivorship: Side Effects and Care Recommendations.晚期乳腺癌生存者：副作用和护理建议。
J Clin Oncol. 2022 May 20;40(15):1604-1610. doi: 10.1200/JCO.22.00049. Epub 2022 Feb 28.
3
Optimal Screening in Breast Cancer Survivors With Dense Breasts on Mammography.乳腺癌幸存者钼靶检查致密乳腺的最佳筛查方法。
J Clin Oncol. 2020 Nov 20;38(33):3833-3840. doi: 10.1200/JCO.20.01641. Epub 2020 Jul 24.
4
Late Recurrence Following Early Breast Cancer.早期乳腺癌的晚期复发。
J Clin Oncol. 2022 May 1;40(13):1400-1406. doi: 10.1200/JCO.22.00167. Epub 2022 Mar 3.
5
Multidisciplinary Management of Breast Cancer With Extensive Regional Nodal Involvement.广泛区域淋巴结受累乳腺癌的多学科管理。
J Clin Oncol. 2020 Jul 10;38(20):2290-2298. doi: 10.1200/JCO.19.03036. Epub 2020 May 22.
6
Surgery No More? Managing the Primary Tumor in Stage IV Breast Cancer.不再进行手术？IV期乳腺癌原发肿瘤的管理
J Clin Oncol. 2022 Mar 20;40(9):927-931. doi: 10.1200/JCO.21.02706. Epub 2022 Feb 4.
7
Improving Outcomes for High-Risk Hormone Receptor-Positive Breast Cancer With CDK Inhibition.CDK 抑制改善高危激素受体阳性乳腺癌的结局。
J Clin Oncol. 2022 Apr 10;40(11):1142-1146. doi: 10.1200/JCO.21.02850. Epub 2022 Feb 24.
8
Navigating Hormone Therapy in Postmenopausal Women: Balancing Symptom Relief With Cancer Risk.绝经后女性激素治疗的抉择：在缓解症状与癌症风险之间寻求平衡。
J Clin Oncol. 2024 Oct 20;42(30):3517-3522. doi: 10.1200/JCO-24-01352. Epub 2024 Sep 20.
9
Should Everyone With Ductal Carcinoma in Situ Receive Adjuvant Radiation?是否所有患有导管原位癌的人都需要接受辅助放疗？
J Clin Oncol. 2021 Nov 10;39(32):3535-3540. doi: 10.1200/JCO.21.01896. Epub 2021 Oct 6.
10
Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than or .乳腺癌女性患者的管理和除 或 以外的其他基因致病性变异。
J Clin Oncol. 2021 Aug 10;39(23):2528-2534. doi: 10.1200/JCO.21.00999. Epub 2021 Jun 9.
本文引用的文献
1
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
2
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.司美格鲁肽治疗射血分数保留的心力衰竭合并肥胖患者的疗效。
N Engl J Med. 2023 Sep 21;389(12):1069-1084. doi: 10.1056/NEJMoa2306963. Epub 2023 Aug 25.
3
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J. 2022 Nov 1;43(41):4229-4361. doi: 10.1093/eurheartj/ehac244.
4
Cardiotoxicity among socioeconomically marginalized breast cancer patients.社会经济地位边缘化的乳腺癌患者的心脏毒性。
Breast Cancer Res Treat. 2022 Oct;195(3):401-411. doi: 10.1007/s10549-022-06695-0. Epub 2022 Aug 15.
5
Cardiometabolic Comorbidities in Cancer Survivors: State-of-the-Art Review.癌症幸存者的心脏代谢合并症：最新综述
JACC CardioOncol. 2022 Jun 21;4(2):149-165. doi: 10.1016/j.jaccao.2022.03.005. eCollection 2022 Jun.
6
Disparities in Cardio-oncology: Effects On Outcomes and Opportunities for Improvement.心脏肿瘤学中的差异：对结果的影响和改善机会。
Curr Cardiol Rep. 2022 Sep;24(9):1117-1127. doi: 10.1007/s11886-022-01732-2. Epub 2022 Jun 27.
7
Cancer treatment and survivorship statistics, 2022.2022 年癌症治疗和生存统计。
CA Cancer J Clin. 2022 Sep;72(5):409-436. doi: 10.3322/caac.21731. Epub 2022 Jun 23.
8
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1.
9
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.定义癌症治疗的心血管毒性：国际心脏肿瘤学会（IC-OS）共识声明。
Eur Heart J. 2022 Jan 31;43(4):280-299. doi: 10.1093/eurheartj/ehab674.
10
Cardiovascular Manifestations From Therapeutic Radiation: A Multidisciplinary Expert Consensus Statement From the International Cardio-Oncology Society.治疗性放疗引起的心血管表现：国际心脏肿瘤学会的多学科专家共识声明
JACC CardioOncol. 2021 Sep 21;3(3):360-380. doi: 10.1016/j.jaccao.2021.06.003. eCollection 2021 Sep.
Zotero 插件